1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Pulmonary Hypertension - Global Market Research 2015-2019

Pulmonary Hypertension - Global Market Research 2015-2019

  • September 2015
  • -
  • Infiniti Research Limited
  • -
  • 65 pages

Summary

Table of Contents

Search Inside

About pulmonary hypertension
Pulmonary hypertension is a rare disorder that affects the pulmonary arteries carrying deoxygenated blood to the lungs from the heart. The narrowing or blockage of pulmonary arteries will lead to pulmonary hypertension. Symptoms of the disease do not occur until the disease becomes severe. Certain causes of pulmonary hypertension include emphysema, connective tissue disorders, blood clots in lungs, and sleep apnea. Pulmonary hypertension may sometimes lead to several chronic illnesses, such as kidney failure (renal failure), heart failure, aneurysm, heart attack, or, stroke. Endothelin receptor antagonists, prostacyclin analogs, phosphodiesterase inhibitors, and sGC stimulators are popular drug therapeutic classes available for the treatment of pulmonary hypertension.

Technavio's analysts forecast the global pulmonary hypertension market to grow at a CAGR of 2.92% over the period 2014-2019.

Covered in this report
The report includes the present scenario and the growth prospects of the global pulmonary hypertension market for the period 2015-2019. To calculate the market size, the report considers revenue generated through the sales of various drugs used in the treatment of pulmonary hypertension.

Technavio's report, Global Pulmonary Hypertension Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. It covers the market size and forecast as well as market segmentation and pipeline landscape. The report includes a discussion of the key vendors operating in this market.

Key Vendors
- Actelion
- Bayer
- GlaxoSmithKline
- United Therapeutics

Other prominent vendors
- Aires Pharmaceuticals
- Arena Pharmaceuticals
- Bial
- DEKA
- Dong-A ST
- Gilead
- Merck
- Northern Therapeutics
- Novartis
- Pfizer
- PhaseBio

Key market driver
- Growing incidence of pulmonary hypertension
- For a full, detailed list, view our report

Key market challenge
- Patent expiry
- For a full, detailed list, view our report

Key market trend
- Increased focus on combination therapies
- For a full, detailed list, view our report


Key Questions Answered in this Report
- What will the market size be in 2019 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
Get This Report
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • January 2017
  • by GlobalData

PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2025 Summary Systemic Lupus Erythematosus (SLE) is a systemic inflammatory autoimmune disease ...

PharmaPoint: Colorectal Cancer - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Colorectal Cancer - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • January 2017
  • by GlobalData

PharmaPoint: Colorectal Cancer - Global Drug Forecast and Market Analysis to 2025 Summary Colorectal Cancer (CRC) Market, considering the sales of both branded treatments and generic chemotherapy, is expected ...

PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • January 2017
  • by GlobalData

PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2025 Summary Ulcerative Colitis (UC) is a type of chronic IBD that causes inflammation and ulcers in the innermost lining of ...

Hnscc: Kol Insight - 2017

March 2017 $ 8355

ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.